Randomized study of the combination of hydroxyurea and interferon alpha versus hydroxyurea monotherapy during the chronic phase of chronic myelogenous leukemia (CML Study II)

R. Hehlmann, H. Heimpel, D. K. Hossfeld, J. Hasford, H. J. Kolb, H. Löffler, H. Pralle, W. Queißer, A. Hochhaus, A. Tichelli, W. Fett, N. Schmitz, A. Reiter, M. Grießhammer, W. Pfeifer, M. Bäumler, T. Kamp, A. Tobler, H. Eimermacher, R. KuseU. Berger, H. Ansari

Research output: Contribution to journalArticlepeer-review

23 Scopus citations

Abstract

It is the long-term goal of the German CML Study Group and off the Suddeutsche Hamoblastosegruppe (SHG) to improve survival of patients with chronic myelogenous leukemia (CML). In a first randomized study (CML Study I) monotherapies with hydroxyurea or interferon alpha (IFN-α) were compared with a standard busulfan regimen with regard to duration of the chronic phase and survival. The main results of this study were published, and a long-term follow up is planned. In a second randomized study the effect of the combination of IFN-α and hydroxyurea versus hydroxyurea monotherapy on survival is being investigated. This paper provides a first preliminary report on the study concept, patient recruitment, state of documentation and initial patients' characteristics 9 months after closure of the study.

Original languageEnglish
Pages (from-to)S21-S24
JournalBone Marrow Transplantation
Volume17
Issue numberSUPPL. 3
StatePublished - May 1996
Externally publishedYes

Keywords

  • Hydroxyurea
  • Interferons
  • Randomized study CML

Fingerprint

Dive into the research topics of 'Randomized study of the combination of hydroxyurea and interferon alpha versus hydroxyurea monotherapy during the chronic phase of chronic myelogenous leukemia (CML Study II)'. Together they form a unique fingerprint.

Cite this